Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

68.07 +1.09 (+1.63%)
Streaming Delayed Price Updated: 11:29 AM EDT, Apr 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts ↗
 
Via Benzinga
News headline image
NASDAQ:HALO is showing good growth, while it is not too expensive. ↗
Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced. 
Via Chartmill
News headline image
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
News headline image
Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
News headline image
(HALO) - Analyzing Halozyme Therapeutics's Short Interest ↗
 
Via Benzinga
News headline image
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
News headline image
NASDAQ:HALO is not too expensive for the growth it is showing. ↗
NASDAQ:HALO is showing good growth, while it is not too expensive. 
Via Chartmill
News headline image
Top 2 Health Care Stocks That May Plunge In August ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Halozyme Therapeutics? ↗
 
Via Benzinga
News headline image
Critical Insights From Halozyme Therapeutics Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): good value for what you're paying. 
Via Chartmill
News headline image
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review ↗
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
News headline image
Looking for growth without the hefty price tag? Consider NASDAQ:HALO. ↗
Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced. 
Via Chartmill
News headline image
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
News headline image
(HALO) - Analyzing Halozyme Therapeutics's Short Interest ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
Will HALOZYME THERAPEUTICS INC Break Out? A Technical Analysis Perspective. ↗
There are signs that NASDAQ:HALO may be ready to breakout. 
Via Chartmill
News headline image
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts ↗
Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped. 
Via Investor's Business Daily
News headline image
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 ↗
On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82. 
Via Investor's Business Daily
News headline image
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying. ↗
When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
3 Biotech Stocks on Track for 50% Returns (or More) by 2028 ↗
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028! 
Via InvestorPlace
News headline image
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark ↗
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier. 
Via Investor's Business Daily
News headline image
NASDAQ:HALO is showing good growth, while it is not too expensive. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is not too expensive for the growth it is showing. 
Via Chartmill
News headline image
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
Beam Therapeutics Stock Earns RS Rating Jump To 85 ↗
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition ↗
These biotech stocks have promising outlooks that will bring major fortune to investors. Buy before it is too late. 
Via InvestorPlace
News headline image
Biotech Arvinas Stock Earns 82 RS Rating ↗
The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82. 
Via Investor's Business Daily
News headline image
Denali Therapeutics Stock Gets Technical Rating Upgrade ↗
Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
News headline image
3 Biotech Stocks to Buy Now: Q3 Edition ↗
Biotech stocks to buy can be a strong portfolio addition due to their capability for rapid growth within an evolving industry. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.